Confusion and conclusion: Avandia, Celebrex and the FDA
This article was originally published in Scrip
Executive Summary
A US FDA advisory panel votes overwhelmingly that a drug increases the incidence of heart attack. It also votes to keep it on the market. Sounds contradictory?